GlassScriptPhysician profile
James B Lekas
NPI 1043205388
$10,069.04
in general payments reported to CMS, 2019-2025
26 companies · $2,422 in 2025
The $2,422 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,410 · 2022: $1,741 · 2023: $2,029 · 2024: $2,467 · 2025: $2,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,918.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,236.98 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,594.21 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,024.18 | 2021-2025 | |
| Incyte Corporation | $891.85 | 2021-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $825.97 | 2021-2025 | |
| Amgen INC. | $624.14 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $356.52 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Dermavant Sciences, INC. | $347.04 | 2023-2024 | Vtama |
| Pfizer INC. | $327.45 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $301.20 | 2021-2024 | |
| Leo Pharma INC. | $212.04 | 2021-2023 | Adbry |
| Lilly USA, LLC | $180.88 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $177.86 | 2024-2025 | Nemluvio |
| Organon LLC | $160.34 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.94 | 2024 | Spevigo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $114.25 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.74 | 2023 | Jublia, Siliq |
| Vyne Pharmaceuticals INC. | $82.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Ucb, INC. | $74.21 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $62.97 | 2023-2024 | Zoryve |
| Mayne Pharma Commercial LLC | $36.69 | 2022 | |
| Biofrontera INC. | $34.22 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $30.22 | 2022 | |
| Organogenesis INC. | $27.44 | 2024 | |
| Merck Sharp & Dohme LLC | $17.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lekas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.